This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-24 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Females are more aggressive than males during the courtship period, often fighting for access to mates, with fights among females accounting for more than half the aggressive interactions during this period. If females court a male that already has a partner, the incumbent female will try to repel the competitor, usually by chasing and kicking. These interactions can be prolonged, lasting up to five hours, especially when the male being fought over is single and neither female has the advantage of incumbency. In these cases, the females typically intensify their calls and displays. The sperm from a mating is stored by the female and can suffice to fertilise about six eggs. The pair mate every day or two, and every second or third day the female lays one of a clutch of five to fifteen very large, thick-shelled, green eggs. The shell is around 1 mm (0.04 in) thick, but rather thinner in northern regions according to indigenous Australians. The shell is substantially composed of calcite, and its δ13C is a function of the emu's diet. The eggs are on average 13 cm × 9 cm (5.1 in × 3.5 in) and weigh between 450 and 650 g (1.0 and 1.4 lb). The maternal investment in the egg is considerable, and the proportion of yolk to albumen, at about 50%, is greater than would be predicted for a precocial egg of this size. This probably relates to the long incubation period which means the developing chick must consume greater resources before hatching. The first verified occurrence of genetically identical avian twins was demonstrated in the emu. The egg surface is granulated and pale green.
The four substrates of this enzyme are 4-hydroxybenzoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are hydroquinone, oxidised NAD+, water, and carbon dioxide. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 4-hydroxybenzoate,NAD(P)H:oxygen oxidoreductase (1-hydroxylating, decarboxylating). This enzyme is also called 4-hydroxybenzoate 1-monooxygenase. This enzyme participates in benzoic acid degradation.
=== Medicinal applications === Erythropoietin (EPO): Epogen from Amgen Granulocyte colony-stimulating factor (G-CSF): filgrastim sold as Neupogen from Amgen; pegfilgrastim sold as Neulasta alpha-galactosidase A: Fabrazyme by Genzyme alpha-L-iduronidase: (rhIDU; laronidase) Aldurazyme by BioMarin Pharmaceutical and Genzyme N-acetylgalactosamine-4-sulfatase (rhASB; galsulfase): Naglazyme by BioMarin Pharmaceutical Dornase alfa, a DNase sold under the trade name Pulmozyme by Genentech Tissue plasminogen activator (TPA) Activase by Genentech Glucocerebrosidase: Ceredase by Genzyme Interferon (IF) Interferon-beta-1a: Avonex from Biogen Idec; Rebif from Serono; Interferon beta-1b as Betaseron from Schering. It is being investigated for the treatments of diseases including Guillain-Barré syndrome and multiple sclerosis. Insulin-like growth factor 1 (IGF-1) Rasburicase, a Urate Oxidase analog sold as Elitek from Sanofi
Sources: en.wikipedia.org
Pediatric dentistry (formerly pedodontics in American English or paedodontics in Commonwealth English) is the branch of dentistry dealing with children from birth through adolescence. The specialty of pediatric dentistry is recognized by the American Dental Association, Royal College of Dentists of Canada, and Royal Australasian College of Dental Surgeons.
== Aquaculture == Farming of Atlantic cod has received a significant amount of interest due to the overall trend of increasing cod prices alongside reduced wild catches. However, progress in creating large scale farming of cod has been slow, mainly due to bottlenecks in the larval production stage, where survival and growth are often unpredictable. It has been suggested that this bottleneck may be overcome by ensuring cod larvae are fed diets with similar nutritional content as the copepods they feed on in the wild Recent examples have shown that increasing dietary levels of minerals such as selenium, iodine and zinc may improve survival and/or biomarkers for health in aquaculture reared cod larvae.
== Fissile vs fissionable == The term fissile is distinct from fissionable. A nuclide that can undergo nuclear fission (even with a low probability) after capturing a neutron of high or low energy is referred to as fissionable. A fissionable nuclide that can undergo fission with a high probability after capturing a low-energy thermal neutron is referred to as fissile. Fissionable materials include those (such as uranium-238) for which fission can be induced only by high-energy neutrons. As a result, fissile materials (such as uranium-235) are a subset of fissionable materials.
== Formation and morphology == During embryonic development, the anterior and posterior pituitary merge due to regulated cell-to-cell interactions, signaling pathways, and numerous transcription factors. Of the pituitary endocrine cells, the gonadotropic cells are the last to form and become functional. It has been found through studies with zebrafish that glycoprotein 𝞪-subunit (gpa) and thyroid-stimulating hormone beta (tshb) expressing cells are precursors for gonadotropes and thyrotropes. Even further, the genes involved in the final differentiation of these precursors into gonadotropes are sine oculus 1 (six1), eyes absent homolog 1 (eya1), steroidogenic factor 1 (sf1), and paired-like homeodomain 1 (pitx1).
Sources: en.wikipedia.org
Infected dogs carry the highest bacterial load of B. canis after 1-6 months after infection. Infected neutered animals are not able to display reproductive symptoms, however both intact and neutered dogs are able to shed B. canis in urine. This means that both neutered and intact dogs are able to transmit the disease via urine. B. canis is found to be localized in the prostate of male dogs, thus transmitting through the urine in both intact and neutered males. It has been suggested that male dogs carry higher concentrations of the bacteria when compared to female dogs due contamination from seminal fluid. Neutered dogs are also capable of shedding the bacteria in their saliva and nasal secretions. B. canis is the least common cause of Brucellosis in humans. Transmission to humans is rarely diagnosed but is possible. It can be transmitted via bodily fluids and aborted material. Signs and symptoms are very non-specific, such as fever, joint pain, and fatigue. The disease can also be debilitating, causing conditions such as endocarditis, splenomegaly, or neurologic symptoms.
==== Medal of the Royal Victorian Order (RVM) ==== In Silver John Nelson Hart, Gamekeeper, Sandringham Estate. Keith Hodson, Stud Hand, Royal Studs. Constable Anthony Claud James, Royalty and Diplomatic Protection Department, Metropolitan Police. John Trodden Kerr, Leading Palace Attendant, Windsor Castle. Leading Marine Engineering Mechanic (Mechanical) Andrew Kevin King, HM Yacht Britannia. Richard Clive Lines, Painter, Sandringham Estate. Musician William Huw Morris, HM Yacht Britannia. Sergeant Paul Andrew George Murrell, Norfolk Constabulary. Peter Leonard Riches, Foreman Gardener, Crown Estate, Windsor. Constable Mervyn John Shrubb, Royalty and Diplomatic Protection Department, Metropolitan Police. David Wetherill, Sacristan, St George's Chapel, Windsor Castle. John Herbert Willison, lately of Truefitt & Hill Limited. Acting Petty Officer Marine Engineering Mechanic (Electrical) Barry John Winstone, HM Yacht Britannia.
== Contraindications == Contraindications of spironolactone include hyperkalemia (high potassium levels), severe and end-stage kidney disease (due to high hyperkalemia risk, except possibly in those on dialysis), Addison's disease (adrenal insufficiency and low aldosterone levels), and concomitant use of eplerenone. It should also be used with caution in people with certain neurological disorders, as well as those who experience or have experienced anuria (lack of urine production), acute kidney injury, or significant impairment of kidney excretory function with risk of hyperkalemia.
Although the following examples illustrate the diversity of point-mutation–mediated disorders, there are over 300,000 such mutations recorded in HGMD and over 1,000,000 variants in ClinVar, reflecting the vast spectrum of human point mutations.
Bergamot essential oil contains a significant amount of bergapten, a phototoxic substance that gets its name from the bergamot orange. Bergapten, a linear furanocoumarin derived from psoralen, is often found in plants associated with phytophotodermatitis. Bergamot essential oil has a higher concentration of bergapten (3000–3600 mg/kg) than any other Citrus-based essential oil. When bergamot essential oil is applied directly to the skin via a patch test, followed by exposure to ultraviolet light, a concentration-dependent phototoxic effect is observed. However, if the oil is twice rectified (and therefore bergapten-free), no phototoxic response is observed. The International Fragrance Association (IFRA) restricts the use of bergamot essential oil due to its phototoxic effects. Specifically, IFRA recommends that leave-on skin products be limited to 0.4% bergamot oil, which is more restrictive than any other Citrus-based essential oil. Although generally recognized as safe for human consumption, bergamot essential oil contains a significant amount of bergamottin, one of two furanocoumarins believed to be responsible for a number of grapefruit–drug interactions. Furanocoumarin contaminants in some berrgamot oil are removed by distillation before the oil is used as a cosmetic.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.